Literature DB >> 15688974

Photodynamic therapy for choroidal neovascular membrane secondary to optic nerve drusen.

Nauman A Chaudhry1, Alejandro J Lavaque, Anish Shah, Peter E Liggett.   

Abstract

The authors describe the use of photodynamic therapy with verteporfin for subfoveal choroidal neovascular membrane secondary to optic nerve drusen. A 28-year-old woman had a peripapillary choroidal neovascular membrane secondary to optic nerve drusen with significant metamorphopsia. Photodynamic therapy using verteporfin was performed. Visual acuity improved to 20/20 with resolution of metamorphopsia and absence of leakage on fluorescein angiography a few weeks after verteporfin therapy. The patient's condition remained stable for 16 months with 20/20 vision. Photodynamic therapy with verteporfin may be a useful treatment option in patients with choroidal neovascular membranes secondary to optic nerve drusen.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15688974

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging        ISSN: 1542-8877


  5 in total

Review 1.  [Optic disc drusen].

Authors:  M Schargus; E Gramer
Journal:  Ophthalmologe       Date:  2008-07       Impact factor: 1.059

Review 2.  Optic Nerve Head Drusen: An Update.

Authors:  Edward Palmer; Jesse Gale; Jonathan G Crowston; Anthony P Wells
Journal:  Neuroophthalmology       Date:  2018-04-25

3.  Paediatric case of peripapillary choroidal neovascularisation associated with optic disc drusen treated with aflibercept.

Authors:  Weh Loong Gan; Vernon W Long
Journal:  BMJ Case Rep       Date:  2019-01-14

Review 4.  Optic disk drusen in children.

Authors:  Melinda Y Chang; Stacy L Pineles
Journal:  Surv Ophthalmol       Date:  2016-03-29       Impact factor: 6.048

5.  Bilateral choroidal neovascularization associated with optic nerve head drusen treated by antivascular endothelial growth factor therapy.

Authors:  Barbara Delas; Lorena Almudí; Anabel Carreras; Mouafk Asaad
Journal:  Clin Ophthalmol       Date:  2012-02-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.